Comprehensive quantitative profiling of tau and phosphorylated tau peptides in cerebrospinal fluid by mass spectrometry provides new biomarker candidates

Journal of Alzheimer's Disease

Volumn 55, Issue 1, 2016, Pages 303-313

  Russell, Claire L ^a   Mitra, Vikram ^a   Hansson, Karl ^b   Blennow, Kaj ^b,c   Gobom, Johan ^b,c   Zetterberg, Henrik ^b,c,d   Hiltunen, Mikko ^e,f   Ward, Malcolm ^a   Pike, Ian ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF EASTERN FINLAND   (Finland)

^f KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

Alzheimer's disease; biomarkers; cerebrospinal fluid; mass spectrometry; neurodegenerative disease; phosphorylation; post translational modifications; tau

Indexed keywords

BIOLOGICAL MARKER; PHOSPHOPEPTIDE; TAU PROTEIN; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MAPT PROTEIN, HUMAN; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ARTICLE; BRAIN TISSUE; CALIBRATOR; CEREBROSPINAL FLUID; EARLY DIAGNOSIS; HUMAN; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION; WORKFLOW; BRAIN CHEMISTRY; CHEMISTRY; COHORT ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; PHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; BRAIN CHEMISTRY; COHORT STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MASS SPECTROMETRY; PEPTIDE FRAGMENTS; PHOSPHORYLATION; TAU PROTEINS;

EID: 84994565894     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-160633     Document Type: Article

References (30)

1. Cohen P (2002) The origins of protein phosphorylation. Nat Cell Biol 4, E127-E130.
2. Gross S, Rahal R, Stansky N, Lengauer C, Hoeflich KP (2015) Targeting cancer with kinase inhibitors. J Clin Invest 125, 1780-1789.
3. Alzheimer?s Association (2015) 2015 Alzheimer?s disease facts and figures. Alzheimers Dement 11, 332-384.
4. Glenner GG, Wong CW (1984) Alzheimer?s disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120, 885-890.
5. Grundke-Iqbal, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-Associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A 83, 4913-4917.
6. Hanger DP, Anderton BH, Noble W (2009) Tau phosphorylation: The therapeutic challenge for neurodegenerative disease. Trends Mol Med 15, 112-119.
7. Johnson GV, Stoothoff WH (2004) Tau phosphorylation in neuronal cell function and dysfunction. J Cell Sci 117, 5721-5729.
8. Feinstein SC, Wilson L (2005) Inability of tau to properly regulate neuronal microtubule dynamics:Aloss-of-function mechanism by which tau might mediate neuronal cell death. Biochim Biophys Acta 1739, 268-279.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer?s disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer?s Disease. Neurology 34, 939-944.
10. Portelius E, Hansson SF, Tran AJ, Zetterberg H, Grognet P, Vanmechelen E, Hoglund K, Brinkmalm G, Westman-Brinkmalm A, Nordhoff E, Blennow K, Gobom J (2008) Characterization of tau in cerebrospinal fluid using mass spectrometry. J Proteome Res 7, 2114-2120.
11. Meredith JE Jr, Sankaranarayanan S, Guss V, Lanzetti AJ, Berisha F, Neely RJ, Slemmon JR, Portelius E, Zetterberg H, Blennow K, Soares H, Ahlijanian M, Albright CF (2013) Characterization of novel CSF Tau and ptau biomarkers for Alzheimer?s disease. PLoS One 8, e76523.
12. Vanmechelen E, Vanderstichele H, Davidsson P, Van Kerschaver E, Van Der Perre B, Sjogren M, Andreasen N, Blennow K (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: A sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285, 49-52.
13. Blennow K, Hampel H, Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144.
14. McAvoy T, Lassman ME, Spellman DS, Ke Z, Howell BJ, Wong O, Zhu L, Tanen M, Struyk A, Laterza OF (2014) Quantification of tau in cerebrospinal fluid by immunoaffinity enrichment and tandem mass spectrometry. Clin Chem 60, 683-689.
15. Dayon L, Sanchez J (2012) Relative protein quantification by MS/MS using the tandem mass tag technology. Methods Mol Biol 893, 115-127.
16. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer?s disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
17. Braak H, Alafuzoff I, Arzberg T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer?s disease-Associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389-404.
18. Robinson MD, McCarthy DJ, Smyth GK (2010) edge R: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139-140.
19. Paulson JN, Stine OC, Bravo HC, PopM (2013) Differential abundance analysis for microbial marker-gene surveys. Nat Methods 10, 1200-1202.
20. De Livera AM, Dias DA, De Souza D, Rupasinghe T, Pyke J, Tull D, Roessner U, McConville M, Speed TP (2012) Normalizing and integrating metabolomics data. Anal Chem 84, 10768-10776.
21. Buchhave P, Blennow K, Zetterberg H, Stomrud E, Londos E, Andreasen N, Minthon L, Hansson O (2009) Longitudinal study of CSF biomarkers in patients with Alzheimer?s disease. PLoS One 4 e6294.
22. Russell CL, Koncarevic S, Ward MA (2014) Posttranslational modifications in Alzheimer?s disease and the potential for newbiomarkers. J Alzheimers Dis 41, 345-364.
23. Barthelemy NR, Gabelle A, Hirtz C, Fenaille F, Sergeant N, Schraen-Maschke S, Vialaret J, Buee L, Junot C, Becher F, Lehmann S (2016) Differential mass spectrometry profiles of tau protein in the cerebrospinal fluid of patients with Alzheimer?s disease, progressive supranuclear palsy, and dementia with Lewy bodies. J Alzheimers Dis 51, 1033-1043.
24. Blennow K, Hampel H (2003) CSF markers for incipient Alzheimer?s disease. Lancet Neurol 2, 605-613.
25. Smet-Nocca C, Broncel M, Wieruszeski JM, Tokarski C, Hanoulle X, Leroy A, Landrieu I, Rolando C, Lippens G, Hackenberger CP (2011) Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation. Mol Biosyst 7, 1420-1429.
26. Qian X, Hamad B, Dias-Lalcaca G (2015) The Alzheimer disease market. Nat Rev Drug Discov 14, 675-676.
27. Hampel H, Buerger K, Zinkowski R, Teipel SJ, Goernitz A, Andreasen N, Sjoegren M, DeBernardis J, Kerkman D, Ishiguro K, Ohno H, Vanmechelen E, Vanderstichele H, McCulloch C, Moller HJ, Davies P, Blennow K (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: A comparative cerebrospinal fluid study. Arch Gen Psychiatry 61, 95-102.
28. Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, Blennow K (2001) Transient increase in total tau but not phospho-Tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297, 187-190.
29. Blennow K, Johansson A, Zetterberg H (2005) Diagnostic value of 14-3-3beta immunoblot and T-Tau/P-Tau ratio in clinically suspected Creutzfeldt-Jakob disease. Int J Mol Med 16, 1147-1149.
30. Zetterberg H, Hietala MA, Jonsson M, Andreasen N, Styrud E, Karlsson I, Edman A, Popa C, Rasulzada A, Wahlund LO, Mehta PD, Rosengren L, Blennow K, Wallin A (2006) Neurochemical aftermath of amateur boxing. Arch Neurol 63, 1277-1280.